hydantoins has been researched along with Retinal Neovascularization in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afzal, A; Caballero, S; Edelhauser, H; Geroski, D; Grant, MB; Hochhaus, G; Jurczyk, S; Miller, RC; Palii, SS; Pan, H; Reubi, JC; Shapiro, G; Shaw, LC; Tan, Y | 1 |
1 other study(ies) available for hydantoins and Retinal Neovascularization
| Article | Year |
|---|---|
Nonpeptide somatostatin receptor agonists specifically target ocular neovascularization via the somatostatin type 2 receptor.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Hormonal; Autoradiography; Cell Movement; Cell Proliferation; Cells, Cultured; Choroidal Neovascularization; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Gene Expression; Humans; Imidazolidines; Injections; Mice; Mice, Inbred C57BL; Octreotide; Ophthalmic Solutions; Polymerase Chain Reaction; Rabbits; Receptors, Somatostatin; Retinal Neovascularization; RNA; Sclera; Treatment Outcome; Vitreous Body | 2008 |